Franco, P., Porta, N., Holliday, J.D. et al. (1 more author) (2017) Molecular similarity considerations in the licensing of orphan drugs. Drug Discovery Today, 22 (2). pp. 377-381. ISSN 1359-6446
Abstract
The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs, i.e., of medicinal products that are designed to treat rare disease that affect only small numbers of patients. Under EU legislation a medicine can only be authorised for treating a specific rare disease if it is not similar to other orphan drugs already authorised for that particular disease. This paper discusses the use of 2D fingerprints to calculate the Tanimoto similarity between potential and existing orphan drugs for the same disease, and presents logistic regression models correlating these computed similarities with the judgements of human experts.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 Elsevier. This is an author produced version of a paper subsequently published in Drug Discovery Today. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
Keywords: | Molecular similarity; orphan drug legislation; rare diseases |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Social Sciences (Sheffield) > Information School (Sheffield) |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 06 Dec 2016 16:41 |
Last Modified: | 29 Jan 2018 11:48 |
Published Version: | https://doi.org/10.1016/j.drudis.2016.11.024 |
Status: | Published |
Publisher: | Elsevier |
Refereed: | Yes |
Identification Number: | 10.1016/j.drudis.2016.11.024 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:108897 |
Download
Filename: Molecular similarity considerations in the licensing of orphan drugs.pdf
Licence: CC-BY-NC-ND 4.0